# NCT06500676 (NCT06500676)

> A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06500676
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Conditions: KRAS G12D Mutations; Advanced Solid Tumors
- Interventions: GFH375
- Enrollment: 407
- Primary outcome: Phase Ia:The incidence and severity of AEs and SAEs
- Primary outcome: Phase Ia:The incidence of DLT events
- Primary outcome: Phase Ib:The incidence and severity of AEs and SAEs
- Primary outcome: Phase II:Overall response rate (ORR)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06500676